# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Joe Frazier (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX004-SYN-TD
- Date: 2008-02-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Clarence Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

Establishing primary care for type 2 diabetes and high blood pressure above goal: A1c, kidney function, urine albumin, lipids, the yearly liver check with FIB-4, eyes, feet and brain health in a former professional boxer. **S**

## Historical basis

- Joe Frazier was born on January 12, 1944, in Beaufort County, South Carolina, the eleventh child of a sharecropping family. **D**
- As a teenager he moved to Philadelphia, where he had relatives, and worked in a slaughterhouse, where he punched sides of beef in the cold room. **D**
- He won the heavyweight gold medal at the 1964 Olympic Games in Tokyo, fighting the final with a broken left thumb. **D**
- Later in 1964 he learned that he had a cataract in his left eye; visually impaired, he turned professional anyway. The cataract grew worse, and by 1975, according to his eye doctor, his vision was 20/50 in the right eye and 20/400 in the left. **D**
- He became undisputed world heavyweight champion in February 1970 and held the title until January 1973, defending it four times; he retired in 1976 after a professional record of 32 wins, 4 losses and 1 draw, with 27 knockouts, and returned for a single bout in 1981. **D**
- His three-fight rivalry in the 1970s included a 1971 victory that handed his opponent his first professional defeat; in the third fight, in Manila in 1975, he could no longer see, and his trainer would not let him come out for the fifteenth round. **D**
- In later life he lived in Philadelphia, where he owned and ran a boxing gym, and he had financial trouble. **D**
- During his life it was reported publicly that he had diabetes and high blood pressure. **D**
- He published an autobiography, Smokin' Joe, in 1996. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- He wants to keep working at his gym and stay strong. **S**
- He worries about the cost of new medicines. **S**
- He wants to know whether the blows he took in the ring will affect his memory. **S**

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Medications and allergies

- Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years **S**
- Lisinopril 20 mg oral tablet, one tablet daily; taken for years **S**
- Atorvastatin 40 mg oral tablet, one tablet daily **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1964: Broken left thumb in the 1964 Olympic final **D** (CLM-0003)
- 1964: Cataract in the left eye found at 20, with reduced vision in that eye through his boxing career (20/400 in that eye by 1975) **D** (CLM-0004)
- 1965 to 1976, and one bout in 1981: Professional heavyweight boxing career with many blows to the head, including a 1975 bout stopped when he could no longer see **D** (CLM-0005, CLM-0006)
- early 2000s: Diabetes and high blood pressure, reported publicly **D** (CLM-0008)

## Procedures and immunizations

- 2008-02-16 to 2008-02-16: Twelve-lead electrocardiogram **S**
- 2008-02-16 to 2008-02-16: Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses **S**
- 2008-02-16: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Hemoglobin A1c: 8.4% (high); Glucose (fasting): 168 mg/dL (high); Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.08 mg/dL; eGFR (CKD-EPI 2003, no race term): 77 mL/min/1.73 m²; Urine albumin-to-creatinine ratio: 18 mg/g; Total cholesterol: 212 mg/dL (high); LDL cholesterol: 132 mg/dL (high); HDL cholesterol: 38 mg/dL (low); Triglycerides: 210 mg/dL (high); AST: 48 U/L (high); ALT: 42 U/L; Alkaline phosphatase: 96 U/L; Albumin: 4 g/dL; Total bilirubin: 0.9 mg/dL; Hemoglobin: 14.2 g/dL; Platelets: 138 10*3/uL (low); Vitamin B12: 340 pg/mL; PHQ-9: 4; AUDIT-C: 2. All results are synthetic.

BP 152/92 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 104 kg; BMI 31.4 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, direct and good-humored; oriented; fluent conversation with good recall of recent events; PHQ-9 score 4. Functional status: Independent in all activities; walks without an aid; reads with his right eye. Physical examination is intentionally limited. **S**

## Assessment

1. Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes; status draft. **S**
2. Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure; status draft. **S**
3. Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated; status draft. **S**
4. Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin; status draft. **S**
5. Obesity, class 1 (BMI 31.4); status draft. **S**
6. Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30; status draft. **S**

## Plan

- Diabetes: continue metformin, an A1c every three months until at goal and then every six months, diabetes self-management education, a vitamin B12 check on long-term metformin, and no medicine that causes low blood sugar. Guideline: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Hepatology consultation for a high FIB-4 with mildly low platelets, with transient elastography and a liver ultrasound the same day. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023) **S**
- Liver assessment: FIB-4 from the yearly liver tests, then transient elastography if FIB-4 is 1.3 or higher; hepatitis B, hepatitis C and HIV tests, iron studies, and an alcohol history. Guideline: 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Blood pressure: a validated home monitor with a large cuff, readings twice a day for a week, a goal below 130/80 mmHg, and less salt. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks; a baseline ECG; aspirin for primary prevention not used because of bleeding risk. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Kidneys: eGFR by the race-free CKD-EPI 2003 equation and urine albumin-to-creatinine ratio at least yearly, and potassium and creatinine on lisinopril. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Eyes and feet: a dilated eye examination at the eye clinic, a comprehensive foot examination yearly, daily foot checks and callus care. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026) **S**
- Brain health: a documented cognitive screen at the preventive visit, blood pressure and glucose control, sleep, hearing and mood checks, and an honest conversation that chronic traumatic encephalopathy cannot be diagnosed during life. Guideline: National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026) **S**
- Cost and access: low-cost generics, 90-day supplies, and help with coverage for any brand-name medicine. Guideline: 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026) **S**

## Guideline basis

- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023), American Association for the Study of Liver Diseases (Hepatology 2023;77(5))
- National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021), Neurology 2021;96(18)
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026), Aether Forge
